EP3689348 - THERAPEUTIC AGENT FOR MEIBOMIAN GLAND DYSFUNCTION [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 24.09.2021 Database last updated on 22.08.2024 | |
Former | Request for examination was made Status updated on 12.02.2021 | ||
Former | The application has been published Status updated on 03.07.2020 | Most recent event Tooltip | 27.04.2024 | New entry: Despatch of examination report + time limit | Applicant(s) | For all designated states Santen Pharmaceutical Co., Ltd. 9-19, Shimoshinjo 3-chome Higashiyodogawa-ku Osaka-shi, Osaka 533-8651 / JP | [2020/32] | Inventor(s) | 01 /
MIYAKE, Hideki c/o SANTEN PHARMACEUTICAL CO., LTD. 8916-16, Takayama-cho Ikoma-shi, Nara 630-0101 / JP | 02 /
ODA, Tomoko c/o SANTEN PHARMACEUTICAL CO., LTD. 8916-16, Takayama-cho Ikoma-shi, Nara 630-0101 / JP | 03 /
SHII, Daisuke c/o SANTEN PHARMACEUTICAL CO., LTD. 8916-16, Takayama-cho Ikoma-shi, Nara 630-0101 / JP | [2020/32] | Representative(s) | Müller-Boré & Partner Patentanwälte PartG mbB Friedenheimer Brücke 21 80639 München / DE | [2020/32] | Application number, filing date | 20164189.1 | 12.03.2014 | [2020/32] | Priority number, date | JP20130050766 | 13.03.2013 Original published format: JP 2013050766 | [2020/32] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3689348 | Date: | 05.08.2020 | Language: | EN | [2020/32] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 10.06.2020 | Classification | IPC: | A61K31/436, A61K9/10, A61K9/107, A61P27/02, A61K31/675, A61P9/06 | [2020/32] | CPC: |
A61K31/436 (EP,CN,KR,US);
A61K31/453 (KR,RU);
A61K31/675 (EP,CN,KR,US);
A61K9/0048 (EP,CN,KR,US);
A61K9/10 (KR);
A61K9/107 (KR);
A61P27/02 (EP,RU);
A61P27/04 (EP);
A61P9/00 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/11] |
Former [2020/32] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | THERAPEUTIKUM FÜR MEIBOMDRÜSENDYSFUNKTION | [2020/32] | English: | THERAPEUTIC AGENT FOR MEIBOMIAN GLAND DYSFUNCTION | [2020/32] | French: | AGENT THÉRAPEUTIQUE POUR LE DYSFONCTIONNEMENT DES GLANDES DE MEIBOMIUS | [2020/32] | Examination procedure | 04.02.2021 | Amendment by applicant (claims and/or description) | 04.02.2021 | Examination requested [2021/11] | 04.02.2021 | Date on which the examining division has become responsible | 23.09.2021 | Despatch of a communication from the examining division (Time limit: M06) | 23.03.2022 | Reply to a communication from the examining division | 26.04.2024 | Despatch of a communication from the examining division (Time limit: M04) | Parent application(s) Tooltip | EP14763999.1 / EP2974728 | Fees paid | Renewal fee | 26.03.2020 | Renewal fee patent year 03 | 26.03.2020 | Renewal fee patent year 04 | 26.03.2020 | Renewal fee patent year 05 | 26.03.2020 | Renewal fee patent year 06 | 26.03.2020 | Renewal fee patent year 07 | 16.03.2021 | Renewal fee patent year 08 | 15.03.2022 | Renewal fee patent year 09 | 09.03.2023 | Renewal fee patent year 10 | 19.03.2024 | Renewal fee patent year 11 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO0009109 (GUILFORD PHARM INC [US]) [A] 1-4 * page 18, lines 8-13 * * claim 7 *; | [A]WO2009025763 (SCHEPENS EYE RES INST [US], et al) [A] 1-4 * paragraph [0019] * * paragraph [0057] ** claims 11, 12 *; | [I]WO2012142145 (DOW PHARMACEUTICAL SCIENCES [US], et al) [I] 1-4 * paragraph [0031] * * claims 1, 2, 4, 6 * * example 3 *; | [AP]WO2013126599 (MASSACHUSETTS EYE & EAR INFIRM [US]) [AP] 1-4 * claims 21, 22 *; | [E]WO2014041071 (NOVALIQ GMBH [DE], et al) [E] 1-4 * page 18, lines 20-32 * * claims 1, 8, 12-14 *; | [A] - Payal Khandelwal ET AL, "Androgen regulation of gene expression in human meibomian gland and conjunctival epithelial cells", Molecular vision, United States, (20120427), pages 1055 - 1067, URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351406/pdf/mv-v18-1055.pdf, (20160616), XP055281056 [A] 1-4 * abstract * | by applicant | JP2002522485 | JP2005516065 | JP2010540682 | JP2012137778 | JP2014024835 | JP2014023526 | - Journal of the Eye, (20100000), vol. 27, no. 5, pages 627 - 631 | - Investigative Ophthalmology & Visual Science, (20110000), vol. 52, no. 4, pages 1930 - 1937 |